The MFDS has launched a full investigation as the risk of impurities in Sartan and Varenicline, a non-smoking treatment supplement, has been raised among hypertension drugs.

Recently, some products have been recalled due to the detection of impurities such as carcinogens in Canada and other countries. However, in the case of Sartan, both raw materials and finished products are planned to be investigated, and in the case of Varenicline, only the finished products were ordered to be tested by related companies.

The MFDS announced on the 22nd that it is conducting a safety investigation of high blood pressure treatment containing satan series and Varenicline, a non-smoking treatment aid.